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Recent advances in our understanding of the human genome have raised high hopes 
for the creation of personalized medicine able to predict diseases well before they 
occur, or that will lead to individualized and therefore more effective treatments. This 
possibility of a more accurate science of the prevention and surveillance of disease 
also illuminates the field of public health, where the translation of genomic 
knowledge could provide tools enhancing the capacity of public health authorities to 
promote health and prevent diseases. But beyond scientific considerations, the use of 
genomics in public health research and interventions gives rise to several ethical and 
social issues of great importance. Considering the impact that PHG could have on the 
future of public health while still paying attention to the uncertainty surrounding the 
use of genomic databases for the benefit of populations, this article seeks to explore 





Recent advances in our understanding of the human genome have raised high hopes 
for the creation of a personalized medicine able to predict diseases long before they 
occur,
2
 or that will produce more effective treatments.
3,4
 This possibility of a more 
efficient science of the prevention and surveillance of diseases also illuminates the 
field of public health, where genomic knowledge could provide tools enhancing the 
capacity of public health authorities to promote health and prevent diseases. 
 
However, a major challenge for public health authorities will be the effective 
integration of genomic information into the public health response, whether it be for 
the identification/treatment of chronic diseases or even infectious ones that constitute 
a serious threat to populations and are costly for the health care system. In order to 
discover and characterize genes associated with diseases, as well as to understand 
how they interact with each other or with the environment to induce illness, some 
experts argue for the development of large biobanks that would gather biological 
materials, genetic, clinical and epidemiological information from large segments of 
the population. These data would facilitate the mapping of genetic variations 
occurring within specific populations and, along with other epidemiological and 
environmental information, could provide crucial insight into genetic susceptibilities 
and environmental threats.  
 
Although genomics could initiate a transformation of the “one size fits all” paradigm 
in public health,
5
 there are concerns about “blind faith” in or overly optimistic views 
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of scientific progress resulting from the most recent research in genomics and 
genetics. Some commentators argue that it is still premature to associate genetic 
variants with the expression of complex diseases.
6
 They argue that, given the 
interaction of the genetic and environmental factors behind complex diseases, the 
attempts to link relevant genes with the expression of the disease are invariably 
simplistic and offer little real hope for practical diagnostics and treatments.  
 
Moreover, beyond scientific considerations, the use of biobanks and genomic 
databases for research and interventions in public health raise important ethical, legal 
and social issues. In addition to privacy concerns related to the use of personal data, 
public health genomics (PHG) deals with the traditional aspects of public health 
interventions, as well as with the fears of stigmatization and discrimination following 
a possible application of genomic tools within at-risk populations (eg, genetic 
screening). 
 
Considering the impact that public health genomics could have for the future of public 
health, but in a context of significant uncertainty surrounding the use of genomic 
information to benefit populations, this article explores the promise of genomics in 
public health and the ethical issues emerging from the translation of genomic 
knowledge into public health interventions.  
 
The integration of genomics into public health 
 
The Human Genome Project ended in April 2003 with the expectation that important 
health benefits would result from current and future genomics research. But the 
growth in genomic knowledge, coupled with improvements in technical capacity (eg, 
bioinformatics), have been tempered by failures in the comprehension of complex 
diseases.
7
 Consequently, the promise of integrating genomics into public health has 
lead to scepticism. 
 
Possibilities of genomics research 
Many human diseases are the result of interactions between genetic variations and the 
environment.
8
 Genomics research is therefore essential for evidence-based disease 
prevention in a public health context. According to Brand and colleagues,  
 
Nowadays, it is known that DNA determines not only the cause of 
single-gene disorders, which affect millions of people worldwide, but 
also predispositions (‘susceptibilities’), which are based on 
genotype and haplotype variants, to common diseases. The new 
technologies will allow researchers to examine genetic mutations at 
the functional, genomic unit level, and to better understand the 
significance of environmental factors such as chemical agents, 
nutrition or personal behavior in relation to the etiology of 





Advocates of public health genomics believe that genomics research will foster the 
development of new genomic tools applicable in a wide variety of public health 
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settings. Genetic services related to maternal and child health (eg, prenatal and 
newborn screening) have been offered in many countries since the early 1960s,
10,11
 
and ongoing efforts and the increasing resources devoted to genomics could 
eventually pave the way for major advances in genetic screening, pharmacogenomics 
and other “-omics” technologies.
12,13
 In spite of their limits,
14
 technology using, for 
example, tandem mass spectroscopy or DNA microarrays are contributing to a finer 
understanding of the association between genetic variation and phenotypes, and are 
considered essential ways for elucidating the genetic determinants of health. With the 
help of these new technologies, genomics research could add to the traditional 
methods of risk assessment and contribute to the achievement of a new genomic 
medicine with significant impacts on public health. Genomics may allow clinicians or 
public health authorities to assess accurately an individual’s risk and to recommend 




It is also expected than some genomics’ applications, such as pharmacogenomics, will 
reduce the costs associated with the traditional “trial and error” method in curative 
medicine.
16
 At the population level, it could also play a substantial role in all aspects 
of public health (promotion, prevention, protection and surveillance). For instance, a 
profitable use of genetic testing, with the aim of providing an optimized and 
personalized drug therapy, can be accomplished by CYP2C9 genotyping.
17
 The allelic 
variants of this gene can identify individuals who show a higher risk of bleeding 
complications due to poor metabolizing of warfarin, an anticoagulant derived from 
coumarin. There are individual differences in response to anticoagulation therapy with 
warfarin derivates, and genotyping facilitates the administration of a therapy adapted 
to the patient’s metabolism. Since anticoagulation therapies are indicated for several 
cardiovascular diseases such as congestive cardiomyopathies, atrial fibrillation, deep 
vein thrombosis or pulmonary embolism, the relevance of such a genomic screening 
method is obvious, both from personalized and public health perspectives. 
 
The expected usefulness of genomics research is not limited to common or chronic 
diseases. Taking into account the damages provoked by tuberculosis, malaria, HIV 
and, more recently, by SARS, some studies have shown the potential of using 
genomic information to prevent pandemics of infectious diseases.
18,19,20
 In addition to 
improving knowledge of the pathogenesis of a disease, or of host-pathogen 
interactions, genomic profiling could help explain patterns of transmission and 
identify allelic variants responsible for disease propagation. Collecting data on genetic 
susceptibility and pathogens could subsequently lead to targeted interventions (eg, 





Successful outcomes in genetic association studies of complex diseases hinge on the 
capacity to replicate results that initially seemed positive. Quite often, problems in 
identifying genetic aetiology of complex diseases are attributable to biological 
complexity and small samples with insufficient statistical power.
22
 This is one of the 
reasons why researchers in genomics have been calling for the creation of large-scale 
genomic databases. Several initiatives to collect genetic and phenotypic information 
for genomic research have been undertaken around the world (DeCode Genetics, 
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Estonia Genome project, UK biobank, CARTaGENE, etc.).
23,24,25
 With this 
information, public health authorities would have the possibility of establishing 
evidence-based strategies to improve population health.
26,27
 The potential usefulness 
of these research infrastructures will to a large extent be determined by their 
functioning and by the nature of the data to which researchers will have access. The 
discoveries emerging from these data will have a deeper impact on public health if 
they are supplemented by other health information concerning, for instance, the 
lifestyles of individuals. The combining of data coming from genomic and other 
health databases will enable, just to give an example, a greater understanding of diet-
related diseases, linking genomic information on gene-food interactions with 
information about diet and individual lifestyles.
28
 In pharmacogenomics, the same 
method would apply to the creation of drug therapies combining clinical information 
with a patient’s genomic profile.  
 
Additionally, the SARS epidemic and concerns about a possible avian influenza 
pandemic have raised experts’ awareness about the importance of implementing 
public health surveillance systems based on real-time epidemic detection and 
monitoring.
29,30
 A genetic vulnerability surveillance system using genomic and health 
databases could allow the detection, in real time or near-real time, of outbreaks of 
infectious and communicable diseases. In brief, whether it be for common diseases, 
drug therapies or infectious diseases, the use of genomic databases cannot be 
dissociated from public health genomics. 
 
The transfer of genomic knowledge in public health 
The translation of new findings in genomics into benefits for the population leads to 
the problem of the transfer of genomic knowledge in public health. Without close 
collaboration between genomics experts and public health policymakers it will be 
difficult to realize the promise of public health improvement by using genomic 
information. 
 
In a recent article, Gwinn and Khoury identified three levels for the integration of 
genomics into public health.
31
 The first is related to the possibility of conducting 
population health research in genomics. As with genomic databases, the impact of 
new findings in genomics could be limited without large cohort studies confirming 
these findings and illustrating the risk factors related to specific diseases. The creation 
of large biobanks and databases, the use of existing samples or the exchange of data 
between researchers, as well as the collaboration of epidemiologists and geneticists, 
as it has been done at the U.S. Centers for Disease Control,
32
 would increase the 
impact of research in public health. South Korea, for instance, provides an example of 
successful exchanges between existing databases. The Korean Multi-center Cancer 
Cohort (KMCC) has collected data on lifestyle, physical activity, diet, reproductive 
factors and agricultural exposure. Moreover, biological materials (blood serum, 
plasma, buffy coat, packed erythrocytes) have been banked for future analysis. In 
2004, the KMCC and other Korean databases regrouped more than 80,000 subjects, 
and the collected data will allow public health authorities to identify risk factors for 
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Because of the difficulties of harmonization between epidemiological studies using 
large genomic databases, both international partnerships and the harmonization of 
parameters, measures and tests are seen as further necessary steps towards the 
integration of genomics in public health practices.
34,35
 It is considered that single 
cohort studies, even with large cohorts, more than likely have insufficient power to 
detect gene-environment interactions for numerous gene variants. As Wichmann and 
colleagues note, “The full potential of cohort studies to shed light on the occurrence 
of complex diseases will probably be realized only by pooling and synthesis across 
multiple populations with different genetic, environmental and sociocultural 
factors”.
36
 Hence the creation of international initiatives, like the Public Population 




 regrouping biobanks and researchers from around the 
world. 
 
The second level concerns the development of scientific evidence regarding the value 
of genomic information. This underlines the importance of disseminating information 
emerging from genomic research to ensure that public health stakeholders receive a 
clear demonstration of the clinical validity and utility of genomics. It implies that the 
education of public health professionals is essential to the success of public health 
genomics.
38
 Public health practitioners should have access to data and training on new 
genomic tools that could bring significant changes in public health. A number of 
recent technologies have proven their clinical value, but to be used properly, public 
health institutions need personnel trained in using sophisticated equipment.
39
 For this 
purpose, international networks are being developed to spread information about 
public health genomics and bring together people from different backgrounds that are 
interested in the possibilities of genomics in public health. HuGeNet
40
 is a good 
example of this kind of network. But these initiatives are still in their infancy and a lot 
has to be done to break down the barriers between genomic experts and their public 
health counterparts. 
 
The third level refers to the integration of genomics into public health practice. 
According to Gwinn and Khoury, the realization of this process requires “careful 
policy planning and development that recognizes the complexity of genomics while 
building on approaches that have been successful in evaluating other health 
technologies”.
41
 The development of an evidence-based decision making process is 




In spite of its numerous expected advantages and its exponential scientific progress, 
public health genomics has raised a number of important ethical concerns.
42,43 
In fact, 
in order to keep its promise of improving public health, public health genomics needs 
to see its scientific progress harmonized with human dignity as expressed through 
adherence to fundamental ethical principles. The ethical issues related to the 
application of genomics in public health must therefore be examined. Some of these 
issues will be the same as those raised by genomics research in general. On the other 
hand, other ethical issues specific to public health will surface.  
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The following sections emphasize the similarities and the differences between a more 
classical approach of the genomics-related ethical issues, which is based on 
Mendelian (monogenic) disorders, and a more contemporary (and relevant) approach 
that takes into account the biological complexity of polygenic disorders. Depending 
on the area of focus (eg, neonatal screening or genetic predispositions to complex 
diseases), an exhaustive ethical reflection on public health genomics should 
encompass both approaches. 
 
Genetic reductionism 
It has been reported that one of the first problem areas that comes to mind in the 
application of genomics toward health improvement is the reduction of human beings 
to their genes.
44
 In addition to the fatalism resulting from a vision where the genes are 
seen as a predominant health determinant, genetic reductionism leads to a major 
redefinition of public health.
45
 It can lead us to put the focus on genetic factors instead 
of also insisting on the importance of healthy behaviours and environments. It creates 
an “individualization” of responsibility
46
 in which individuals are carriers of 
inheritable “genetic defects” that represent a threat to public health. This situation 
might minimize the moral duty of the collectivity to provide equitable access to 
environmental health determinants such as healthy food, housing, education, etc. 
Genetic reductionism also results in a situation where individuals are experiencing a 
loss of hope in an open and undetermined future. It has been argued that the question 
of reductionism is largely outmoded since it is generally accepted that a majority of 
diseases are multifactorial, that is, they are the results of genetic and environmental 
factors.
47
 In fact, many highly prevalent diseases, such as type 2 diabetes, are also 
conditioned by environmental factors (eg, diet and lifestyle), which means that 
genetic testing only reveals predispositions instead of clear clinical diagnostic 
information. It is then important not to forget the other health determinants for 
preventing a fatalistic attitude from at-risk people. In that sense, public health 
genomics emphasises the complexity of biological processes, the importance of gene-
gene and gene-environment interaction, and explicitly points out that its power lies in 
the application of mainstream public health interventions – healthy behaviours or 
environmental manipulation – but directed at sub-groups of the population segmented 
according to genetic risk. Genes are indeed a major health determinant but no more 
(or no less) major than environmental factors. Both contribute to disease risk. 
 
Protection of privacy 
Given that the integration of genomics into public health implies the use of genomic, 
phenotypic and epidemiological data, the questions linked to privacy and consent are 
at the centre of ethical reflection. First, by its nature, genomic information can help 
predict a person’s medical future and divulge information about family members. For 
those reasons, genetic information is sometimes considered unique and deserving of 
special consideration, a view known as “genetic exceptionalism”.
48,49 
 
For many authors, a focus on genetic exceptionalism is not justified since the 
predictive value of genetic information is often limited, especially in the context of 
complex diseases.
50
 In addition, non-genetic biomarkers such as cholesterol level or 
blood pressure often have a greater predictive value than genotypic markers (except in 
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the case of high penetrance inherited disorders). Consequently, for those authors, 




Second, the complexity of privacy issues is also underscored by the possible 
commercialization of biological tissues, by the need to transfer or exchange 
information from one database to another and by the secondary use of data.
53
 
Guidelines have been proposed over the last few years for ensuring the respect of 
human dignity and the protection of human rights and fundamental freedoms.
54,55
 
Moreover, in order to maintain a balance between the protection of individual rights 
and the creation of biobanks and genomic databases as public goods,
56,57
 and in order 
to take into account the unforeseeable aspects of genomic research, different consent 




Third, the multiple potential uses of collected data seem to speak in favor of a broad 
consent instead of a specific one. This form of consent would include a right of 
withdrawal and transparency about the goals and the results of the research.
60
 This 
solution appears to be a good compromise between a “blanket consent” (unspecified 
uses of samples), which infringes on the right of the participant to be informed, and a 
strict notion of direct and ongoing informed consent, which is not always suitable for 
genomic research.
61
 The notions of “waivers” (alteration of some or all the elements 
of informed consent) and “multi-layered consent” have also been proposed to solve 
this delicate but fundamental problem.
62
 But even so, tension still persists between 
those who wish to reduce the formalities and facilitate research and those who wish to 
promote the right of the participant to be informed. 
 
Privacy and confidentiality are closely linked to the level of consent. For instance, 
with anonymized or anonymous samples, it becomes possible to consider a broad 
consent, because the person is not identifiable. However some research projects 
require the linking of genetic information with clinical information, which is of the 
greatest importance for developing personalized treatment and prevention programs. 
Consequently, different coding procedures need to be developed to meet research 
objectives.
63
 Obviously, to ensure the smooth running of the identity protection 




Stigmatization and discrimination 
The collection and storage of data for public health genomics opens individuals and 
communities to the threat of stigmatization and discrimination. One of the most 
common fears about genetic testing is the possibility of being penalized by insurance 
companies or by employers if individuals are found to be carriers of a genetic 
mutation.
65,66
 The potential discrimination differs from the one based on “visible” 
differences, but the logic is similar: to separate “good” genes from “abnormal” 
genes.
67
 In some of its applications (eg, genetic screening), this logic of separation 
could lead to a form of eugenics which might become socially acceptable because the 
selection would be made under the pretext of improving public health. 
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The implementation, through public health genomics research, of more accurate 
methods of prevention and surveillance, to prevent infectious diseases for example, 
brings out the stigmatization and discrimination issues encountered in public health 
ethics. Which segment of the population will be subject to surveillance and on what 
grounds? Is there a risk of stigmatizing these sub-populations because of their genetic 
susceptibilities? Will the use of genomic technologies lead to new inequalities among 
people? Even if the risks of stigmatization or discrimination might be exaggerated, 
they might have negative impacts on research, especially on the recruitment of 
subjects and the fears might prevent the development of public health genomics and 
its benefits to populations. Such questions underline the importance, for public health 
genomics, of not loosing sight of the ethical principles at the root of public health 
ethics.
68,69,70
 Yet, the literature is sparse that addresses public health genomics and 
public health ethics. Articles on the ethical aspects of genomics are more concerned 
with research ethics, while articles on public health ethics present problems related to 
traditional approaches to public health. 
 
Individual versus collective rights 
In an era of heightened human rights awareness, the use of public health authorities’ 
power is becoming more and more complicated.
71
 This also holds for pubic health 
genomics. The use of genomics as a privileged tool of research, prevention, protection 
or surveillance in a public health context provides an example of a classic problem in 
public health ethics: the respect of both individual and collective rights. 
 
On the one hand, there is the obligation to respect individuals’ rights based on their 
autonomy and privacy, whether it be in the collection of biological materials and data 
or in the implementation of measures for improving public health. On the other hand, 
there is the right of the whole population to be protected against environmental 





Public Health Genomics (PHG), with its actions undertaken at the population level, 
necessitates the emergence of an ethical paradigm that goes beyond the clinical and 
individual-based principle of autonomy.
73
 It has been suggested that, in public health 
interventions, the precautionary principle may serve as the starting point of a new 
ethics of risk management,
74,75
 which could be applicable to PHG. Ethical rules 
inspired by John Stuart Mill’s harm principle
76
 limit preventive interventions to a 
minimum in order to protect individuals against the violation of their rights. 
Interventions are justified only if the risk is significant. But according to the 
precautionary principle, there is an “obligation to protect populations against 
reasonably foreseeable threats, even under conditions of uncertainty”.
77
 Thus, the 
precautionary principle highlights the potential harm of inaction and points to the 
importance of scientific assessment of risk. This interventionist approach to public 
health was applied in Europe when cases of mad cow disease were reported.
78
 Given 
the added value that risk management based on the study of gene-environment 
interactions represents, and since an individualistic vision of autonomy could put a 
brake on the evolution of PHG, the precautionary principle is seen as part of a 
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solution, bridging the gap and easing the tension between individual and collective 
rights. 
 
The concept of “public good” might also be a part of the solution to this ethical 
dilemma.
79
 It stipulates that in an era of liberalism and globalization, the creation of 
public goods compensates for the inequalities resulting from an inequitable 
distribution of genomic technologies. “Global public goods are defined as goods that 
are both non-competitive and non-exclusive. They are, in other words, enjoyable by 
all without detriment to others.”
80 
To some experts, genomic databases correspond to 
the definition of a public good because they are universally accessible resources. They 
belong to the common heritage of mankind and should therefore not be patented for 
private use.
81
 In this perspective, by promoting a “common ownership” of genomic 
knowledge, by improving public health and by tailoring interventions for 
communities, the creation of genomics research infrastructures could be perceived as 
a public goods that respond to the most fundamental needs of individuals (eg, equity, 





To the extent required by their status of public resource, there is a moral obligation to 
return to the population, at least partially, the benefits yielded by genomics research 
infrastructures.
83,84
 Benefit-sharing can take various forms
85
: research on conditions or 
issues that are important to the community, training for local researchers, providing 
access to information and services generated by genomics research, free or reduced-
price access to tests or treatments developed through genomics research, and creation 
of local infrastructure and employment opportunities, etc.
 
 
In an international perspective, a transfer of knowledge and technologies to 
developing countries could be proposed to reduce social and economic inequalities 
among nations. Whatever form it takes, benefit-sharing should be supported by a clear 
ethical vision. Should benefit-sharing be motivated by solidarity with vulnerable 
communities? Should we consider the idea of sharing financial benefits? Or should 
only health benefits be shared? 
 
In the absence of a clear ethical vision about benefit-sharing, participation in research 
projects involving genomic databases might be compromised, and eventually, 
concrete and tangible benefits of public health genomics for the directed population 
might be questioned. 
 
Public participation 
Because citizens have been or will be solicited as research subjects, because they 
support the risks of genomics research as well as benefit from its results, and because 
of the power imparted to public health authorities, the ethical integration of genomics 
into public health requires the informed awareness of lay citizens, and eventually their 
participation in the formulation of public policy. Otherwise, the situation might 
evolve toward the creation of social inequalities or cause undesirable harms. Growing 
disparities between experts and non-experts are contrary to the ideal of transparency. 
Consequently, great attention should be paid to the role of the public in PHG. Most 
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genetics experts recognize the importance of public awareness.
86,87,88 
Great attention is 
accorded to informing the public, but this often leads to a one-sided dialogue that 
doesn’t afford lay citizens much influence in policy-making.
89,90
 Increasingly, 
however, voices are emerging on the theme of public participation in biotechnology 
policy-making.
91,92,93
 From consensus conferences to citizens’ workshops, various 
mechanisms have been set up to increase the influence of the lay citizenry. Still, even 
if the idea of enrolling citizens is in keeping with democratic values, many questions 
remain. First, public participation models are expensive and their organization is very 
time-consuming. Do the results make up for the costs? Second, given the complexity 
of genomics-related issues, lay citizens must be trained by experts to facilitate the 
debate with other experts. Is there a risk of being biased? Third, to be democratic, 
these mechanisms must be representative. How can this representativeness be attained 
and thereafter evaluated? 
 
These questions show that the efficacy and efficiency of public participation models 
must be fully thought through. From the diversity of citizens’ personal experiences a 
“popular wisdom” could emerge and represent an added value for policy-making in 
PHG. But the extent to which the public should be engaged remains an unsolved 




Scientific research using genomic infrastructures aims to offer new opportunities to 
improve public health. Recent advances in pharmacogenomics suggest that it will be 
possible to apply personalized treatments adapted to the genomic profile of each 
patient. The idea of a new genomic medicine provides hope for an improved and more 
cost-effective management of disease. 
 
The implementation of genomic-based strategies could also bring a significant 
contribution to the redefinition of public health. The translation of genomic 
knowledge into clinical practice reveals the possibility of changing not only the way 
research in public health is conducted, but also how subsequent interventions may be 
carried out. For instance, the prevention of chronic diseases and the promotion of 
healthy behaviours could be facilitated by the predictive capacity of more 
sophisticated genetic tests. Furthermore, the creation of databases containing genomic 
information on populations and on pathogens, supported by new data processing 
tools, could help redesign surveillance systems in which outbreaks of infectious 
diseases would be detected earlier than with traditional methods. 
 
However, technical, economic, legal and ethical barriers may hinder the advent of 
public health genomics. The realization of the full potential of PHG is still years 
ahead and the investments needed are substantial. The social costs of potential 
discrimination, stigmatization or invasion of privacy add further obstacles. The long-
term development of PHG will require an appropriate integration of the scientific, 
economic and ethical dimensions. Public participation might also contribute to the 
integration process. Considering that, ultimately, the whole population will have, at 
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least in part, to support the economic and social costs of PHG, it is therefore crucial to 
take the views of the public fully into account. 
 
To date, little has been done to help PHG stakeholders (genomics and public health 
scientists, policy-makers, health care providers, etc.) to ethically integrate genomics 
into public health planning. Many grey areas subsist around those ethical principles 
that should be applied to PHG (eg, consent, secondary use of data). That is why major 
fieldwork should be undertaken with stakeholders as well as the public, to obtain a 
wide range of views and opinions, which could lead to the development of a suitable 
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